Archive for the 'Trimodality Therapy' Category
Preoperative chemotherapy and postoperative radiation.
October 24th, 2007. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
Conclusions: Our results suggest that the sequential administration of cisplatin followed by Mapatumumab or Lexatumumab deserves investigation in the treatment of patients with MPM.
October 3rd, 2007. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center
Conclusions: In addition to tumor histology and pathologic stage, predictors of survival include gender, asbestos exposure, smoking, symptoms, laterality, and clinical stage. Surgical resection in a multimodality setting was associated with improved survival.
Posted in CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pleurectomy/decortication, Staging, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
September 22nd, 2007. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
Conclusions: Pleural biopsy performed using thoracoscopy is considered to be the cornerstone of the diagnosis and pleural staging of MPM. However, this procedure appears to be less efficient in diagnosing the histologic subtype as either epithelial or biphasic.
August 4th, 2007. Multidisciplinary Treatment of Malignant Pleural Mesothelioma
However, currently available treatments still appear to have modest results. Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease.
Posted in Chemotherapy, Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, New & Novel, Pemetrexed (Alimta), Pleural, Radiation, Raltitrexed (Tomudex), Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 3rd, 2007. The MARS trial: mesothelioma and radical surgery
Can radical surgery cure mesothelioma or add usefully to the length and quality of life for its victims? The MARS (mesothelioma and radical surgery) trial is open and recruiting in Britain. If the trial proves feasible we will seek to make an international study.
April 14th, 2007. Treatment of malignant pleural mesothelioma
As other treatment methods, chemohyperthermia, treatments using various kinds of cytokines and angiogenesis inhibitors, genetic treatment and photodynamic therapy have been attempted. The current treatment results for this disease are very poor, and there has been a strong demand for establishing an effective treatment method.
Posted in Angiogenesis, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gene Therapy, New & Novel, Pemetrexed (Alimta), Photodynamic Therapy (PDT), Pleural, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 6th, 2007. Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study
Conclusion: The four-modality treatment that we adopted for advanced-stage MPM was feasible, well tolerated by most of the patients, and produced a favorable median survival. This treatment approach warrants further investigation.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Pleural, Pleurectomy/decortication, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 4th, 2007. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results
Conclusions: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity. Our results are similar to those of other studies using a heavier modality treatment.
Posted in Carboplatin, Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Pleural, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 16th, 2007. The role of radiotherapy in the treatment of malignant pleural mesothelioma
There is no role for radical radiotherapy alone, but the role of radiotherapy as part of multimodality therapy is discussed. There have been studies of intensity-modulated radiotherapy as part of multimodality therapy and this technique needs to be evaluated further.
January 26th, 2007. Survey of surgical treatment of malignant pleural mesothelioma in Japan
086) with a marginal significance, indicating that complete surgical resection of the tumor and perioperative adjuvant therapy could be effective treatment for MPM in Japan. Thus, the development of multimodality therapy including surgical treatment for this disease may be required to improve surgical results of MPM patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pleurectomy/decortication, Sarcomatoid, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 26th, 2006. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma
Conclusions: The multimodality treatment we adopted for stage II-III MPM was feasible, well tolerated by most of the patients and produced a favourable outcome. New targeted therapies are awaited for further improvements in the treatment of this disease.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Epithelioid, Full Archive, Gemcitabine (Gemzar), Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Pneumonectomy, Radiation, Sarcomatoid, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 13th, 2006. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma
Conclusions: This series confirms the reproducibility of the trimodality treatment for MPM,which is associated with prolonged survival for early-stage tumors at the cost of a not prohibitive treatment-related mortality rate.
September 15th, 2006. Malignant mesothelioma – diagnosis and treatment strategies
Combined modalities have a better prognosis in selected patients with epithelioid histology, clear resection margins, and no positive extrapleural nodes. Chemotherapy using new antimetabolite agents in combination with platinum compounds is useful for palliation and can improve both survival and quality of life compared with single-agent cisplatin.
September 12th, 2006. Cardiac tamponade complicating trimodal therapy for malignant mesothelioma
We report here a case of hypotension secondary to tension hydrothorax in which echocardiography and hemodynamic monitoring demonstrated evidence of tamponade physiology. Thoracentesis was lifesaving.
September 6th, 2006. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma
Conclusions: NVP-AEW541 has a concentration-dependent inhibitory effect on mesothelioma cells in culture. NVP-AEW541 acts by inhibition of IGF-1R phosphorylation. Inhibition effects phosphorylation of downstream mediators in a dose-dependent fashion. Inhibition of the IGF pathway decreases viability of mesothelioma cell culture. Further evaluation of NVP-AEW541, and other selective IGF-1R inhibitors, may play an important role in multimodal treatment of malignant mesothelioma.
June 6th, 2006. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
Conclusions: Intensity-modulated RT treatment for mesothelioma after EPP and adjuvant chemotherapy resulted in a high rate of fatal pneumonitis when standard dose parameters were used. We therefore recommend caution in the utilization of this technique. Our data suggest that with IMRT, metrics such as V5 and MLD should be considered in addition to V20 to determine tolerance levels in future patients.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, IMRT, Intrapleural Chemotherapy, Pemetrexed (Alimta), Pleural, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 14th, 2005. Multimodality approach in management of malignant pleural mesothelioma
Cisplatin and mitomycin have demonstrated modest efficacy in management of distant tumor recurrence. Cisplatin and gemcitabine regimen as well as cisplatin/pemetrexed followed by 54Gy of adjuvant hemithorax radiation have been reported to improve the outcome.
December 8th, 2005. Diagnosi precoce e terapie integrate del mesotelioma pleurico maligno
palliative, proved to be useful in the treatment of two major symptoms, namely dyspnea and thoracic pain. In this work the Authors are reporting their experience with malignant pleural mesothelioma, stressing the role of videothoracoscopy in the early diagnosis, weighing the radical cancer resection option and the effectiveness of multimodal treatment.
December 6th, 2005. Radiotherapy for mesothelioma
Locoregional tumor recurrence can be eliminated with combinations of extrapleural pneumonectomy and radiation therapy. Survival in early-stage patients is excellent.
|
|  |
